AUGUST 25, 2016

Economy News  Giving a big push to the infrastructure sector in the country, the Cabinet Committee on Economic Affairs approved nine projects worth about Rs 240 bn in nine states for expansion of railway network and connectivity across the country. (ET)  The Union Cabinet approved a revised Double Tax Avoidance Agreement between India and Cyprus that provides for source-based taxation of capital gains on transfer of shares instead of one based on residence. (BS)  Monsanto Co has withdrawn an application seeking approval for its next generation of genetically modified cotton seeds in India, a major escalation in a long-running dispute between New Delhi and the world's biggest seed maker. (Livemint)  In order to check pollution, a new policy will be framed to make scrapping of 15-year old vehicles mandatory, bringing heavy vehicles in its ambit to begin with, Union Minister Nitin Gadkari said. The Finance Ministry has suggested putting the proposed policy before a Committee of Secretaries, the Road Transport and Highways Minister said after holding a meeting with Finance Minister. (ET)  Seeking to reduce carbon emissions, the government said that a new efficiency rating system for air-conditioners, based on Indian climatic conditions, will be made compulsory for all models starting January 2018. (Livemint)

Corporate News  AstraZeneca Pharma India has received a notice of termination from AstraZeneca UK, conveying its decision for termination of distribution agreement for Meronem (meropenem) in India. This is as a result of a global agreement by AstraZeneca PLC to sell the development and commercialisation rights to Pfizer Inc, of its late-stage small molecule antibiotics business. (BS)  Tata Global Beverages may "restructure" China operations. According to Cyrus P Mistry, Chairman of Tata Group, there are challenges in these operations. (BL)  Ending a long-run dispute over its shareholding, leading commodity exchange MCX said it has entered into an agreement with stock bourse MSEI to settle their dispute over warrant cancellation out of court. (ET)  Swedish home furnishing giant IKEA AB said it would continue doing business with Welspun India while it awaits the outcome of the Indian textile manufacturer's probe into its sales practices. (Reuters)  State Bank of India is planning to raise capital of up to Rs 111 bn through additional Tier-I (AT-1) bonds from domestic and international investors. (BS)  Lupin said its subsidiary Gavis Pharmaceuticals has received approval from the US health regulator to market generic linezolid tablets used for treating bacterial infection in the American market. According to IMS MAT June sales data, Zyvox tablets had US sales of $273.6 million. (BS)  8K Miles Software Services Ltd announced its plans to raise Rs5 bn through a mix of instruments including issue of equity shares or convertible bonds through qualified institutional placement (QIP), among others. (BL)  Indo Count Retail Ventures P. Ltd (ICRVL), a subsidiary of Indo Count Industries Limited (ICIL), has announced its entry into Rs 130 bn domestic bed linen market with the launch of 'Boutique Living' range of Bed Linen products. (BL) Source: ET = Economic Times, BS = Business Standard, FE = Financial Express, BL = Business Line, ToI: Times of India, BSE = Bombay Stock Exchange

Equity % Chg 24 Aug 16

1 Day 1 Mth 3 Mths

Indian Indices SENSEX Index NIFTY Index BANKEX Index SPBSITIP Index BSETCG INDEX BSEOIL INDEX CNXMcap Index SPBSSIP Index

28,060 8,650 22,209 10,659 14,939 10,803 15,161 12,515

0.2 0.2 0.0 0.4 (0.0) 1.5 0.7 0.7

(0.1) 0.2 2.2 (0.9) (4.7) 1.9 4.1 2.3

8.4 9.0 15.1 (5.9) 12.5 18.8 16.8 14.3

World Indices Dow Jones Nasdaq FTSE NIKKEI HANGSENG

18,481 5,218 6,836 16,597 22,821

(0.4) (0.8) (0.5) 0.6 (0.8)

(0.1) 2.4 1.9 (0.4) 3.6

3.5 6.6 9.1 (1.2) 11.9

Value traded (Rs cr) 24 Aug 16

% Chg - Day

2,815 18,386 480,738

(10.3) (0.1) 6.5

Cash BSE Cash NSE Derivatives

Net inflows (Rs cr) 23 Aug 16

% Chg

MTD

YTD

6 132

(106) (32)

7,950 350

38,833 9,139

FII Mutual Fund

FII open interest (Rs cr)

FII FII FII FII

23 Aug 16

% Chg

28,512 75,592 64,937 6,937

2.8 3.4 2.3 (1.5)

Index Futures Index Options Stock Futures Stock Options

Advances / Declines (BSE) 24 Aug 16

A

B

T

Advances Declines Unchanged

183 113 4

662 500 37

40 33 4

Total % total 885 646 45

Commodity

56 41 3

% Chg 24 Aug 16 1 Day 1 Mth 3 Mths

Crude (US$/BBL) Gold (US$/OZ) Silver (US$/OZ)

46.8 1,327.2 18.6

0.1 (1.1) (1.9)

8.5 0.4 (5.1)

(5.5) 8.4 14.4

Debt / forex market 24 Aug 16 1 Day 1 Mth 3 Mths 10 yr G-Sec yield % Re/US$

7.1 67.1

7.1 67.1

7.2 67.4

7.5 67.8

Sensex 28700 27200 25700 24200 22700 Aug-15

Nov-15

Feb-16

M ay-16

Aug-16

MORNING INSIGHT

August 25, 2016

ANALYST MEET UPDATE

GLAXOSMITHKLINE PHARMACEUTICALS LTD

Meeta Shetty, CFA [email protected] +91 22 6218 4425

PRICE: RS.3070

RECOMMENDATION: NOT RATED

We attended the analyst meet of Glaxo Pharma, Glaxo has been facing pressure since last two years since the implementation of NLEM policy in Sep-2013. To revive growth Glaxo has earmarked huge capex for the next three years and is also looking at launching few products from its parent Glaxo UK's patented product basket in the Indian Pharma Market. Valuations for Glaxo is far higher than the large caps in the pharma space comparatively and is expected to remain so. Below are the key takeaways from the analyst meet :

Summary table (Rs mn)

CY13 FY15*

FY16

Sales 25383 32725 27411 Growth (%) (3.2) 28.9 (16.2) EBITDA 5282 6330 4789 EBITDA margin (%) 20.6 19.2 17.3 PBT 6853 8076 5769 Net profit 4817 4764 3768 EPS(Rs) 56.9 56.2 44.5 Growth (%) (14.3) (1.1) (20.9) CEPS(Rs) 59.2 59.2 47.4 BVPS(Rs) 234.9 215.9 200.2 DPS (Rs) 50.0 62.5 50.0 ROE (%) 24.2 26.0 22.2 ROCE (%) 30.6 38.3 29.0 Net debt (20,480) (19,080) (13,461) NW Capital (Days) 20.6 14.5 24.2 P/E (x) 53.6 54.2 68.5 P/BV (x) 13.0 14.1 15.2 EV/Sales (x) 9.36 7.30 8.92 EV/EBITDA (x) 44.98 37.76 51.08 Source: Company, Kotak Securities - Private Client Research; *FY15 numbers are for 15 months

Revenue break up – FY16

 Glaxo remains a market leader in the vaccines segment in India (within the private sector market).  Glaxo markets ~140 drugs along with 250 SKU's in the Indian Pharma Market (IPM). Glaxo has an MR strength of ~2500 and this has been constant over the past 1-2 years.  Glaxo has planned a huge capex of over Rs 10.0 bn to be spent over the next 2-3 years. The capex is mainly towards a new facility in Vemgal, Karnataka and expansion of Nashik plant. Of the total capex, ~Rs 2.2bn has already been spent in FY16, Rs 6.3bn will be spent in FY17E and the rest in FY18E.  Company expects the Vemgal facility to be readied by 1QFY18 and expects it to attain higher capacity utlisation by the second year of operations. The payback period for this plant is expected to be ~5 years.  Glaxo expects its current capacity of ~12 bn units (including Nashik and CMOs) to double to ~24bn unit's post this capex spend of Rs 10.0bn. The major addition will come from Vemgal plant (which has a capacity of ~9.0bn units at double shift) and rest from Nashik expansion. The total number of CMOs which currently are at 24 and will come down to 20 in next 2 years.  As far as new launches are concerned, Glaxo plans to launch total 7 products over the next 3 years from its parent's portfolio (most of the drugs are under patent). The launches include 3 products in the respiratory segment, 3 vaccines, 1 diabetes and one 1 probiotic product.  Glaxo is on the lookout for inorganic opportunities through in-licensing or acquisitions.  The NLEM portfolio contribution as of FY16 stood at 23%. The DPCO (price cut) impact for 1QFY17 was at Rs 0.20bn and would be ~Rs 1.0bn for FY17E. Glaxo has not been impacted much due to the FDC (Fixed Dose Combination) ban as they have limited drugs in the combination category. Glaxo expects the price increases to be ~5-6% every year (companies are allowed to take a price increase of ~10% on brands every fiscal, but competitive pressures allow companies to take a nominal increase).

Source: Company

 Glaxo had an outstanding cash balance of Rs 13.3bn as of FY16.  Glaxo has been facing constraints from its CMO (contract manufacturers) which led to a hit of Rs 3.5bn (Rs 2.0bn - Vaccines, Rs 0.50 - Neosprin, Rs 1.0bn other Rx) on revenues in FY16 and Rs 0.55bn hit in 1QFY17. Brand Neospirin was the key product hit due to the constraints particularly in 1QFY17 (Rs 0.50bn + for FY16 and Rs 0.35bn in 1QFY17). Company expects the supplies to restore for Neosprin and hence the supply constraints in coming quarters would be ony ~Rs 0.20bn / per quarter. Due to the restoring of supplies, Company expects Neospirin to gain back its revenue run-rate of Rs 1.2bn on a yearly basis.

Kotak Securities Limited has two independent equity research groups: Institutional Equities and Private Client Group. This report has been prepared by the Private Client Group. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Equities Research Group of Kotak Securities Limited. Kotak Securities - Private Client Research

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

2

MORNING INSIGHT

August 25, 2016

 Over the past year Glaxo has been seeing a strong volume growth in few of its key products wherein Augmentin has posted over 100% growth in FY15 and 57% growth in FY16. Seretide (post price cut) has grown at 100% in FY16. Synflorix (where the price cut has been ~40%) has grown at 64%). The Rabies Vaccine has grown at 90% to ~Rs 1.20bn brand in FY16 and the base vaccine business is growing at 50%.  Company is targeting an EBIDTA margin of ~20% going ahead and the key drivers would be (1) reducing impact of supply constraints (2) Gross margin improvement (3) Capital investments (4) DPCO recovery.  On GST, the company indicated that the rate at which GST will be implemented is very critical for the industry. Management believes, a rate of 1315% (which is also proposed by the industry) will lead to benefits in form of speed of delivery and better working capital management but any rate over 18% will lead to lower profitability. Revenue trajectory

Margins trajectory

Source: Company, *FY15 numbers are for 15 months

Source: Company, *FY15 numbers are for 15 months

Profit trajectory

Return ratios

Source: Company, *FY15 numbers are for 15 months

Source: Company, *FY15 numbers are for 15 months

Cash rich balance sheet

Working capital cycle

Source: Company, *FY15 numbers are for 15 months

Source: Company, *FY15 numbers are for 15 months

Kotak Securities - Private Client Research

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

3

MORNING INSIGHT

August 25, 2016

ENGINEERS INDIA LTD (EIL)

RESULT UPDATE Ruchir Khare [email protected] +91 22 6218 6431

PRICE: RS.252 TARGET PRICE: RS.335

RECOMMENDATION: BUY FY18E P/E: 15.8X

EIL reported Q1FY17 results, much higher than our estimate, driven by meaningful growth in the consultancy orders execution and provision write back in LSTK (Lumpsun Turnkey Projects). Order inflows improved significantly in the quarter (highest in past eight quarters) driven by domestic hydrocarbon business. Management shared encouraging outlook for the domestic business and expects significant pickup in order inflows over 9MFY17/FY18. Management revised its FY17 order flows guidance to Rs 35 Bn from Rs 20 Bn earlier. Summary table (Rs mn)

FY16 FY17E FY18E

Sales 14,958 Growth (%) (12.7) EBITDA 1,600 EBITDA margin (%) 10.7 PBT 3921 Net profit 2,583 EPS (Rs) 7.7 Growth (%) (15.3) CEPS (Rs) 8.4 BV (Rs/share) 79.1 DPS (Rs) 5.0 ROE (%) 9.9 ROCE (%) 9.8 Net cash (debt) 26,238 NW Capital (Days)(131.3) EV/Sales (x) 3.9 EV/EBITDA (x) 36.7 P/E (x) 32.9 P/Cash Earnings (x) 30.0 P/BV (x) 3.2

16,386 9.5 3,605 22.0 6198 4,153 12.3 60.7 12.9 84.8 5.7 15.0 14.9 26,652 (83.9) 3.6 16.3 20.4 19.5 3.0

19,626 19.8 5,299 27.0 7885 5,362 15.9 29.1 16.5 94.1 5.7 17.8 17.6 30,393 (84.2) 3.0 11.1 15.8 15.2 2.7

Source: Company, Kotak Securities - Private Client Research

We reiterate our positive view on EIL and sharply revise our FY18 earnings estimate to factor in 1) improved order flows/execution driven by improved capex spending by domestic oil refineries and 2) improved profitability driven by higher proportion of consultancy orders. We have maintained in our earlier updates that EIL stock's rerating would track its order book growth. In the improved business environment (shared by the management and other industry players), at PER of 16.9x (FY18 core earnings; adjusted for cash) we believe that EIL stock is trading at attractive valuation. We expect EIL to significantly outperform the benchmark index in next 6-9 months; change valuation methodology (ascribe PER of 25x on FY18 core earnings, earlier valued on DCF basis) and maintain BUY rating with revised price target of Rs 335 (Rs 210 earlier) on company's stock. We expect company to report cash at Rs 28 Bn in FY18. Quarterly financials (Rs mn)

Q1FY17

Q1FY16

YoY %

Q4FY16

QoQ%

Revenues

3418

3914

(12.7)

2864

19.3

Employee expenses

1552

1550

0.2

1418

9.5

Sub-Contract Payments

349

617

(43.4)

305

14.6

Construction Material

127

1072

(88.2)

235

(46.0) 29.0

Other expenses

661

331

99.6

512

Total Expenses

2689

3569

(24.7)

2470

8.9

EBITDA

729

345

111.4

394

84.9

Other income

546

577

(5.4)

663

(17.7)

Depreciation EBIT Net Interest PBT

53

85

(37.6)

59

(10.2)

1222

837

46.0

998

22.4

0

0

1222

837

0 46.0

998

22.4

Total tax

422

301

40.3

304

38.9

PAT

800

536

49.2

694

15.2

49.2

EPS (Rs)

2.4

1.6

2.1

15.2

EBITDA (%)

21.3

8.8

13.8

55.0

Tax Rate (%)

34.6

36.0

30.5

13.5

Source: Company

Kotak Securities Limited has two independent equity research groups: Institutional Equities and Private Client Group. This report has been prepared by the Private Client Group. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Equities Research Group of Kotak Securities Limited. Kotak Securities - Private Client Research

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

4

MORNING INSIGHT

August 25, 2016

Result Highlights Revenue declined 12.7% YoY to Rs 3.4 Bn in Q1FY17 due to lower execution in LSTK segment due to depleting order backlog. Operating margin, however expanded sharply to 21.3% from 8.8% in Q1FY16 due to 1) increased proportion of PMC (Project Management Consultancy) division which attracts higher margins (PMC margins improved 300 bps YoY) and 2) provision write back in LSTK segment (trend expected to continue in 9MFY17). EBITDA increased 111.4% YoY, reported at Rs 729 mn in Q1FY17. Adjusted for provision write back (net impact Rs 95 mn), EBITDA margin would have been at 18.6%. In Q1FY17, PMC division reported 19.4% YoY increase in sales, reported at Rs 2.7 Bn. EBIT margin for the segment stood at 23.4% vis-à-vis 20.2% in Q1FY16 due to operating leverage. LSTP division revenues stood at Rs 732 mn in Q1FY17 vis-à-vis Rs 1.6 Bn in Q1FY16. LSTP division reported operating profit of Rs 271 mn vis-à-vis Rs 83 mn in Q1FY16 driven by provision write back. EIL reported provision write back of Rs 270 mn against Rs 310 mn provision made in Q4FY16. It also made fresh provision of Rs 130 mn against contractual obligation and Rs 45 mn for doubtful debt in Q1FY17. Thus net impact of provision write back has been close to Rs 95 mn in the quarter. Management stated that since most of the LSTK orders are over (or are at the verge of closure; currently EIL has two orders from ONGC and CPCL in backlog) such reversals would continue to get reported in next few quarters as well. EIL's order book is now concentrated around PMC division and LSTK revenue booking will remain small going ahead. Employee cost at Rs 1.5 Bn remained flat YoY in the quarter. Management stated that employee cost would likely remain at the current levels. Other costs including input costs are expected to come down with growing PMC volumes. Other income stood at Rs 546 mn in the quarter on back of strong balance sheet. EIL reported cash at close to Rs 26 Bn (close to Rs 79 per share) at the end of FY16. Segment Results (Rs mn)

Q1FY17

Q1FY16

YoY (%)

Q4FY16

QoQ (%)

Revenues PMC (Project management consultant)

2686

2251

19.4

2733

(1.7)

732

1655

(55.8)

1310

(44.1)

PMC (Project management consultant)

628

455

38.1

794

(20.9)

Lumpsum Turnkey Projects (LSTK)

271

83

227.7

-194

PMC (Project management consultant)

23.4

20.2

29.0

Lumpsum Turnkey Projects (LSTK)

37.0

5.0

-14.8

Lumpsum Turnkey Projects (LSTK) EBIT

Segment Margins %

Source: Company

Order inflows improved in the quarter; FY17/FY18 order inflows expected to pick up on back of tighter emission norms and brownfield expansions by OMCs EIL's order backlog grew substantially to Rs 54.6 Bn in the quarter against Rs 37.8 Bn in the end of FY16. Currently, PMC order book stands close to Rs 35.7 Bn (65% of total order book) and turnkey orders stands at Rs 18.9 Bn. Order inflows reported at Rs 20 Bn in the quarter (against Rs 4.9 Bn in Q1FY16), includes Rs 8.3 Bn and Rs 12.2 Bn of PMC and LSTK orders respectively. In FY16, order inflows stood at Rs 15.9 Bn which were primarily consultancy orders.

Kotak Securities - Private Client Research

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

5

MORNING INSIGHT

August 25, 2016

Management expects significant pickup in domestic order flows over FY17/FY18 and has revised order inflows guidance to Rs 35 Bn against Rs 20 Bn earlier. Order flows are likely to be driven by 1) upgradation of key refineries to BS-VI norms by the year 2020 (most of the orders already awarded/won by the company in Q1FY17), 2) large orders like Maharashtra refinery (40 mn tonnes project; value Rs 1 trillion, PMC scope could be 5-7% of total cost) to be executed by HPCl, BPCL, IOCL and HPCL Vizag refinery, 3) brownfield expansion of various refineries is likely to pick up and non-Hydrocarbons orders like Namami Ganga should also report growth. Management has also stated that most of the prospective orders would be in PMC division and execution shall pick up from Q3FY17 onwards. We concur with the management's view and note that the long term prospects of the business appears strong as strengthened financial health of OMCs (on back of low oil prices) augers well for EIL's business. Management had earlier stated that large greenfield orders van directly be assigned to EIL and not through competitive bidding. We note that this is a big positive for the company. Some of the potential orders can arise from the following Hydrocarbon expansion plans over FY17/18.

Project

Client

Scope

Estimated Consultancy Jobs Rs Bn

Bina refinery expansion

BPCL

Expansion from 6 mn MT to 7.8 mn MT

Bina refinery expansion

BPCL

9 mn MT Grassroot expansion

9 to 10

Kochi propylene derivatives

BPCL

Propylene derivatives

2.5 to 5

Bhatinda Expansion

HPCL

a) Low cost initial expansion. B) Doubling of capacity. C) Petrochemical integration.

4 to 4.5

1 to 1.25

Numaligarh Expansion

BPCL

Expansion of Vishakhapatnam refinery

HPCL

Expansion by 9 mn mt

Na

Barauni Refinery

IOC

Expansion by 6 mn MT and petrochemical integration

West Coast refinery

IOC

BPCL, HPCL, IOC

4 to 5 Na 9 to 10

Source: Company, Kotak Securities - Private Client Research

On overseas business front, EIL has moderated its positive view on Middle East and Africa orders. We believe that lower crude oil prices could lead to deferment in few overseas orders. Small/medium ticket sized orders would keep on getting awarded even at currently lower crude oil price level. Progress in Dangote refinery (contract value close to Rs 10 Bn), Nigeria has been satisfactory so far. Management has received payment of close to Rs 2 Bn from this job. Initiatives w.r.t. diversification into new areas like water management, Solar, Nuclear power and fertilizers are progressing at a reasonable pace. Management reiterated that sizable opportunities can arise in smart cities space. In Q1FY17, EIL reported entry level order of Rs 800 mn from Namami Ganga (potential size could be Rs 6 Bn). Similar orders are likely to be awarded in future as well.

Kotak Securities - Private Client Research

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

6

MORNING INSIGHT

August 25, 2016

List of Key Orders awarded (bagged) in Q1FY17

Source: Company

Company to maintain high growth in financials; asset light business model likely to result in value accretion We project revenue growth at 15% CAGR between FY16-18 from Rs. 14.9 Bn in FY16 to Rs. 19.6 Bn in FY18E driven mainly by improved order flows/execution in the domestic hydrocarbon business. We also expect timely execution in the international orders, especially Dangote project. We highlight that the proportion of PMC revenues is likely to increase in the overall revenue pie over FY17/18 and would lead to significant margin expansion going forward. Within the revenue streams, we expect PMC revenues to grow at 24% CAGR in the same period. We expect LSTK revenues to contract (despite winning Rs 12 Bn worth of orders in Q1FY17) as most of the orders are at the closure stage currently. Segment revenues (Rs bn)

20.00

Consultancy & Engineering

LSTP

15.00 10.00 5.00 0.00 FY14

FY15

FY16

FY17E

FY18E

Source: Company, Kotak Securities - Private Client Research

Kotak Securities - Private Client Research

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

7

MORNING INSIGHT

August 25, 2016

We also believe that in FY17, operating margins will also be aided by provision write backs against closure of various LSTK projects which are currently at terminal stage. Further, we believe that most of the orders bagged recently, would start getting executed from Q4FY7 onwards. This would have an escalating effect on FY18 (and beyond) margins due to operating leverage (management guided to keep employee cost and other overheads at current levels; higher utilization rate expected drive EBITDA margin). We therefore build EBITDA margin at 21% and 27% in FY17 and FY18 respectively (significant revision in earnings; refer table below) in our projected financials. We expect PMC margins to expand to 28-30% in FY18. We expect PAT to grow at 44% CAGR between FY16-18 and core PAT at 97% CAGR (also aided by small base of FY16) in the same period. Margin trend

EBITDA Rs bn (LHS)

EBITDA% (RHS)

6.00

30.00

5.00

25.00

4.00 3.00

20.00

2.00

15.00

1.00

10.00

0.00 FY14

FY15

FY16

FY17E

FY18E

Source: Company, Kotak Securities - Private Client Research

We highlight that the company has a strong debt free balance sheet with net cash amounting to nearly Rs 79 per share. Lower capex and negative working capital would boost free cash flow generation in future. Change in earning estimate

Revenue

Revised

FY17 Old

% Chg

Revised

FY18 Old

% Chg

16386

16599

-1.3

19626

19,390

1.2

EBITDA

3605

2,988

20.6

5299

4,072

30.1

EBITDA (%)

22.0

18.0

27.0

21.0

PAT

4153

3,739

11.1

5362

4,604

PAT (Core)

2277

1,863

22.2

3457

2,807

23.2

EPS

12.3

11.1

11.0

15.9

13.7

16.1

6.8

5.5

22.0

10.3

8.3

23.6

EPS (Core)

16.5

Source: Kotak Securities - Private Client Research

 Increase revenue growth and operating margin estimates to factor in improved ordering/execution in domestic hydrocarbon orders in FY17/18.  We build higher proportion of PMC sales over FY17/18 (against earlier assumption) which is a high margin business. Change in revenue mix would have lower impact on sales estimate but much higher impact on the EBITDA.  We arrive at target price of Rs 335 (Rs 210 earlier).

Kotak Securities - Private Client Research

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

8

MORNING INSIGHT

August 25, 2016

Valuation Table (Rs mn) Core PAT

3,457

PER (x)

25

Net Cash

26238

Fair valuation

112659

Fair Valuation (Target Price) (Rs)

335

Source: Kotak Securities - Private Client Research

Valuation and recommendation We have maintained in our earlier updates that EIL stock's rerating would track order book growth. In the improved business environment (shared by the management and other industry players), at PER 16.9x (FY18 core earnings; adjusted for cash) we believe that EIL stock is trading at attractive valuation. We maintain BUY on Engineers India Ltd with a price target of Rs.335

Kotak Securities - Private Client Research

We expect EIL to significantly outperformance the benchmark index in next 9-12 months; change valuation methodology (ascribe PER of 25x on FY18 core earnings, earlier valued on DCF basis) and maintain BUY rating with revised price target of Rs 335 (Rs 210 earlier) on company's stock.

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

9

MORNING INSIGHT

Bulk deals

August 25, 2016

Trade details of bulk deals Date

Scrip name

24-Aug

BRPL

24-Aug

BRPL

24-Aug

BULL

24-Aug

BULL

24-Aug

BULL

24-Aug

Name of client

Buy/ Sell

Quantity of shares

Avg. price (Rs)

Hem Sec Ltd

S

1,04,000

34.5

Hem Chand Jain

B

1,00,000

34.5

Jayesh Rawal

B

27,000

20.6

Rakesh Navinchandra Sheth

S

25,000

21.0

Piyush Shah

S

25,000

21.0

CHROMATIC

Ambe Securities Pvt Ltd

S

15,00,000

3.8

24-Aug

INDIANACRY

Dheeraj Garg

B

12,75,340

17.8

24-Aug

INTELLADV

Olumpus Trading & Advisory Llp

B

7,75,000

14.4

24-Aug

INTELLADV

Sunil Optics Pvt Ltd

S

7,75,000

14.4

24-Aug

KAPILCO

Sangam Advisors Ltd

S

5,500

145.0

24-Aug

LINKPH

Madras Parameswaran M Mahadev

B

23,674

10.6

24-Aug

LINKPH

Raj Kumar Pasricha

S

22,540

10.6

24-Aug

NTCIND

Yashaswi Dugar

S

1,20,055

53.4

24-Aug

NTCIND

Loka Properties Pvt Ltd

B

2,41,605

53.7

24-Aug

NTCIND

Moti Lal Dugar Huf

S

67,200

54.5

24-Aug

PRISMMEDI

Gurudev Arbitrators Pvt Ltd

B

10,000

25.0

24-Aug

PRISMMEDI

Prakash Bai

S

18,400

25.0

24-Aug

PURSHOTTAM

Lani Merchandise Private Ltd

B

50,000

6.5

24-Aug

SANGFROID

Vishnuprasad Somabhai Patel

S

26,160

1.5

24-Aug

SUPREMETEX

Ajay Gupta

S

3,64,992

8.3

24-Aug

SYSCO

Atul Bhandari

S

40,000

23.0

24-Aug

VJTFEDU

Sam Financial Services Llp

B

93,889

53.0

24-Aug

VJTFEDU

Ajay Dilkush Sarupria

S

94,000

53.0

Source: BSE

Gainers & Losers

Nifty Gainers & Losers Price (Rs)

chg (%)

Index points

Volume (mn)

Gainers Aurobindo Pharma Maruti Suzuki Tata Power

788

7.0

NA

7.4

4,949

2.4

NA

1.0

76

2.2

NA

10.4

Losers Idia Cellular Lupin Ltd Tata Motors -

98

(2.6)

NA

14.4

1,522

(2.2)

NA

1.5

323

(1.5)

NA

1.2

Source: Bloomberg

Kotak Securities - Private Client Research

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

10

MORNING INSIGHT

August 25, 2016

RATING SCALE Definitions of ratings BUY

–

We expect the stock to deliver more than 12% returns over the next 9 months

ACCUMULATE

–

We expect the stock to deliver 5% - 12% returns over the next 9 months

REDUCE

–

We expect the stock to deliver 0% - 5% returns over the next 9 months

SELL

–

We expect the stock to deliver negative returns over the next 9 months

NR

–

Not Rated. Kotak Securities is not assigning any rating or price target to the stock. The report has been prepared for information purposes only.

RS

–

Rating Suspended. Kotak Securities has suspended the investment rating and price target for this stock, either because there is not a sufficient fundamental basis for determining, or there are legal, regulatory or policy constraints around publishing, an investment rating or target. The previous investment rating and price target, if any, are no longer in effect for this stock and should not be relied upon.

NA

–

Not Available or Not Applicable. The information is not available for display or is not applicable

NM

–

Not Meaningful. The information is not meaningful and is therefore excluded.

NOTE

–

Our target prices are with a 9-month perspective. Returns stated in the rating scale are our internal benchmark.

Fundamental Research Team Dipen Shah IT, Economy [email protected] +91 22 6218 5409

Ruchir Khare Capital Goods, Engineering [email protected] +91 22 6218 6431

Meeta Shetty, CFA Pharmaceuticals [email protected] +91 22 6218 6425

Jayesh Kumar Economy [email protected] +91 22 6218 5373

Sanjeev Zarbade Capital Goods, Engineering [email protected] +91 22 6218 6424

Ritwik Rai FMCG, Media [email protected] +91 22 6218 6426

Jatin Damania Metals & Mining [email protected] +91 22 6218 6440

K. Kathirvelu Production [email protected] +91 22 6218 6427

Teena Virmani Construction, Cement [email protected] +91 22 6218 6432

Sumit Pokharna Oil and Gas [email protected] +91 22 6218 6438

Pankaj Kumar Midcap [email protected] +91 22 6218 6434

Arun Agarwal Auto & Auto Ancillary [email protected] +91 22 6218 6443

Amit Agarwal Logistics, Paints, Transportation [email protected] +91 22 6218 6439

Nipun Gupta Information Technology [email protected] +91 22 6218 6433

Technical Research Team Shrikant Chouhan [email protected] 91 22 6218 5408

Amol Athawale [email protected] +91 20 6620 3350

Derivatives Research Team Sahaj Agrawal [email protected] +91 79 6607 2231

Rahul Sharma [email protected] +91 22 6218 5498

Kotak Securities - Private Client Research

Malay Gandhi [email protected] +91 22 6218 6420

Please see the Disclosure/Disclaimer on the last page

Prashanth Lalu [email protected] +91 22 6218 5497

For Private Circulation

11

MORNING INSIGHT

August 25, 2016

Disclosure/Disclaimer Kotak Securities Limited established in 1994, is a subsidiary of Kotak Mahindra Bank Limited. Kotak Securities is one of India's largest brokerage and distribution house. Kotak Securities Limited is a corporate trading and clearing member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), Metropolitan Stock Exchange of India Limited (MSEI). Our businesses include stock broking, services rendered in connection with distribution of primary market issues and financial products like mutual funds and fixed deposits, depository services and Portfolio Management. Kotak Securities Limited is also a depository participant with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). Kotak Securities Limited is also registered with Insurance Regulatory and Development Authority as Corporate Agent for Kotak Mahindra Old Mutual Life Insurance Limited and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI). We are registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advise/warning/ deficiency letters/ or levied minor penalty on KSL for certain operational deviations. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time. We offer our research services to clients as well as our prospects. This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions. This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients of Kotak Securities Ltd. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable though its accuracy or completeness cannot be guaranteed. Neither Kotak Securities Limited, nor any person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Kotak Securities Limited has two independent equity research groups: Institutional Equities and Private Client Group. This report has been prepared by the Private Client Group. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Equities Research Group of Kotak Securities Limited. We and our affiliates/associates, officers, directors, and employees, Research Analyst(including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of Research Report or at the time of public appearance. Kotak Securities Limited (KSL) may have proprietary long/short position in the above mentioned scrip(s) and therefore may be considered as interested. The views provided herein are general in nature and does not consider risk appetite or investment objective of particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with KSL. Kotak Securities Limited is also a Portfolio Manager. Portfolio Management Team (PMS) takes its investment decisions independent of the PCG research and accordingly PMS may have positions contrary to the PCG research recommendation. Kotak Securities Limited does not provide any promise or assurance of favourable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. No part of this material may be duplicated in any form and/or redistributed without Kotak Securities' prior written consent. Details of Associates are available on our website ie www.kotak.com Research Analyst has served as an officer, director or employee of subject company(ies): No We or our associates may have received compensation from the subject company(ies) in the past 12 months. We or our associates may have managed or comanaged public offering of securities for the subject company(ies) in the past 12 months. We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months. We or our associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months. We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report. Our associates may have financial interest in the subject company(ies). Research Analyst or his/her relative's financial interest in the subject company(ies): No Kotak Securities Limited has financial interest in the subject company(ies): No Our associates may have actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relatives has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No Kotak Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No Subject company(ies) may have been client during twelve months preceding the date of distribution of the research report. "A graph of daily closing prices of securities is available at www.nseindia.com and http://economictimes.indiatimes.com/markets/stocks/stock-quotes. (Choose a company from the list on the browser and select the "three years" icon in the price chart)." Kotak Securities Limited. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. CIN: U99999MH1994PLC134051, Telephone No.: +22 43360000, Fax No.: +22 67132430. Website: www.kotak.com/www.kotaksecurities.com. Correspondence Address: Infinity IT Park, Bldg. No 21, Opp. Film City Road, A K Vaidya Marg, Malad (East), Mumbai 400097. Telephone No: 42856825. SEBI Registration No: NSE INB/INF/INE 230808130, BSE INB 010808153/INF 011133230, MSEI INE 260808130/INB 260808135/INF 260808135, AMFI ARN 0164, PMS INP000000258 and Research Analyst INH000000586. NSDL/CDSL: IN-DP-NSDL-23-97. Our research should not be considered as an advertisement or advice, professional or otherwise. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and the like and take professional advice before investing. Investments in securities are subject to market risk; please read the SEBI prescribed Combined Risk Disclosure Document prior to investing. Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts. Compliance Officer Details: Mr. Manoj Agarwal. Call: 022 - 4285 8484, or Email: [email protected]. In case you require any clarification or have any concern, kindly write to us at below email ids:  Level 1: For Trading related queries, contact our customer service at '[email protected]' and for demat account related queries contact us at [email protected] or call us on: Online Customers - 30305757 (by using your city STD code as a prefix) or Toll free numbers 18002099191 / 1800222299, Offline Customers - 18002099292  Level 2: If you do not receive a satisfactory response at Level 1 within 3 working days, you may write to us at [email protected] or call us on 02242858445 and if you feel you are still unheard, write to our customer service HOD at [email protected] or call us on 022-42858208.  Level 3: If you still have not received a satisfactory response at Level 2 within 3 working days, you may contact our Compliance Officer (Name: Manoj Agarwal ) at [email protected] or call on 91- (022) 4285 8484.  Level 4: If you have not received a satisfactory response at Level 3 within 7 working days, you may also approach CEO (Mr. Kamlesh Rao) at [email protected] or call on 91- (022) 4285 8301. Kotak Securities - Private Client Research

Please see the Disclosure/Disclaimer on the last page

For Private Circulation

12